Hualan Biological

Hualan Biological is a Chinese biopharmaceutical company headquartered in Xinxiang, Henan, and principally associated with human plasma-derived medicines and vaccine manufacturing. Established in 1992, the company developed within China's blood-products sector, where manufacturers collect donated plasma, subject it to pathogen-control and fractionation processes, and produce therapeutic immunoglobulins, coagulation factors, albumin and related biological medicines. Its business has also included vaccine research, development and production through the Hualan Vaccine business, giving the group exposure to both plasma-derived therapies and preventive biologics. The company's plasma-products portfolio has historically included human albumin, human immunoglobulin preparations, intravenous immunoglobulin, specific immunoglobulins and coagulation-related products such as factor VIII and fibrinogen, subject to product registrations and regulatory approvals. These medicines are used in settings including immune deficiency, infection-related complications, bleeding disorders, trauma and other hospital indications. Plasma-derived products are highly regulated because their safety depends on donor screening, controlled collection, validated viral-inactivation or removal procedures, batch testing and traceability throughout the manufacturing chain. Hualan Biological expanded its activities through manufacturing capacity, plasma-collection networks, research and development, and affiliated or subsidiary operations. Its vaccine activities have included seasonal influenza vaccines and other human vaccines developed or manufactured under Chinese regulatory authorization. During the COVID-19 pandemic, the company and related vaccine operations were involved in research and development efforts concerning COVID-19 vaccination, although product availability and regulatory status have varied by program and time. The company became a publicly traded Chinese enterprise when its shares were listed on the Shenzhen Stock Exchange in 2004 under ticker 002007. Public-company reporting has made capacity expansion, plasma collection, product approvals, quality management, procurement conditions, and healthcare-policy changes recurring themes in its disclosures. Its commercial position is primarily domestic: it serves Chinese hospitals, public-health institutions, distributors and vaccination channels, while its products and technologies may also be subject to international registration or cooperation requirements where applicable. Hualan Biological operates in a sector shaped by scarce plasma resources, strict biological-product regulation, public-health demand and pricing pressure. Its competitive strengths are generally associated with manufacturing experience, a portfolio of plasma-derived products, collection and supply-chain infrastructure, and participation in China's vaccine industry. At the same time, the business faces risks from changes in plasma collection, product quality or safety events, government procurement and reimbursement policies, manufacturing compliance, clinical and regulatory uncertainty, and fluctuations in demand for vaccines and hospital medicines. It remains an active listed biopharmaceutical company rather than a consumer-facing brand in the conventional sense.

Hualan Biological originated in 1992 in Xinxiang, Henan, as a Chinese enterprise working in biological medicines. Its development took place during the expansion and modernization of China's blood-products industry. Unlike conventional pharmaceutical products, plasma-derived medicines depend on a specialized raw-material system: qualified plasma must be collected from approved donation sites, tested, pooled under controlled conditions, fractionated into therapeutic proteins and subjected to validated safety controls. Building this system requires long-term investment in collection facilities, cold-chain logistics, production equipment, quality laboratories and regulatory compliance. The company established its principal identity around human plasma-derived products. Its portfolio has included albumin, immunoglobulins, intravenous immunoglobulin, specific immunoglobulins and coagulation-related products. These medicines serve hospital and public-health needs and are used in different clinical circumstances, including immune disorders, severe illness and bleeding-related care. Product composition, indications and commercial availability depend on Chinese registration approvals and manufacturing authorization. Hualan Biological subsequently broadened its biological-products activities through research and development, manufacturing expansion and vaccine-related operations. Vaccine work added a second major capability to the group, allowing it to participate in seasonal influenza and other human-vaccine programs. The vaccine business became particularly visible during the COVID-19 pandemic, when Chinese pharmaceutical companies and research institutions undertook multiple vaccine-development programs. Hualan-related operations participated in such efforts, although vaccine candidates and programs have different development, authorization and commercialization outcomes. The company was listed on the Shenzhen Stock Exchange in 2004 under stock code 002007. As a listed company, it has disclosed information concerning production capacity, plasma collection, product registrations, subsidiaries, research projects and market conditions. Public reporting also reflects the structural pressures of China's healthcare market, including government tendering, centralized or volume-based procurement initiatives, hospital purchasing, reimbursement policy and regulation of biological-product quality. Hualan Biological's history is therefore best understood as the evolution of a regulated Chinese biopharmaceutical manufacturer rather than simply a branded consumer-product company. Its core assets are manufacturing know-how, product registrations, plasma supply and collection infrastructure, quality systems and scientific capabilities. The company continues to face industry-specific constraints: plasma is a limited biological input; production batches require extensive testing; safety failures can have serious consequences; and vaccine and plasma-product markets are sensitive to public-health policy, clinical demand and regulatory decisions.

1. 2020COVID-19 vaccine research period

   Hualan-related vaccine operations participated in COVID-19 vaccine research and development activities during the pandemic.

   Source
2. 2004Shenzhen Stock Exchange listing

   The company became publicly listed in Shenzhen under stock code 002007.

   Source
3. 1992Company established

   Hualan Biological was established in Xinxiang, Henan, beginning its development as a Chinese biological-medicines enterprise.

   Source

A Chinese regulated biopharmaceutical manufacturer combining plasma-derived therapeutic products with vaccine research and production.

• Human albuminPlasma-derived medicine

  Human albumin is a plasma-derived protein used in hospital medicine for specified conditions involving volume support, low serum albumin and other approved clinical indications. Production depends on screened donor plasma, fractionation, purification, viral-safety controls and batch release testing.

• Human immunoglobulin productsPlasma-derived medicine

  This group includes normal and specific immunoglobulin preparations derived from human plasma. Depending on the product, they are used for immune replacement or passive protection under approved medical indications. Availability and labeling are governed by Chinese drug-registration and biological-product rules.

• Intravenous immunoglobulinPlasma-derived medicine

  Intravenous immunoglobulin is a purified plasma-derived preparation administered in hospitals for approved immune-related indications. Its manufacture requires controlled plasma pooling, purification, pathogen-reduction or removal measures, sterility controls and extensive quality testing.

• Coagulation factor and fibrinogen productsPlasma-derived medicine

  Hualan Biological's plasma-products activities include coagulation-related medicines such as fibrinogen and factor products. These therapies are intended for specified bleeding or coagulation disorders and require specialized fractionation, potency testing and strict regulatory control.

• Seasonal influenza vaccinesHuman vaccine

  The company's vaccine operations have included seasonal influenza vaccines for prevention of influenza infection. Vaccine composition, approved age groups, manufacturing method and commercial status depend on the relevant regulatory approvals and annual strain-selection cycle.

• 2020Participate in COVID-19 vaccine developmentProduct launch

  The COVID-19 pandemic created urgent demand for vaccines and prompted Chinese vaccine manufacturers to initiate multiple research and development programs.

  What changed. Hualan-related vaccine operations entered COVID-19 vaccine research and development activities.

  Aftermath. The work expanded the public-health and vaccine-development profile of the group, while the outcome and authorization status of individual programs depended on subsequent regulatory evaluation.

  Source
• 2004Use public-market financing to support biological-products expansionStrategy

  After developing in China's plasma-products sector, the company entered the public capital market to support continued corporate and manufacturing development.

  What changed. Hualan Biological completed its Shenzhen Stock Exchange listing under stock code 002007.

  Aftermath. The listing made the company subject to ongoing public disclosure and connected its expansion plans with investor, regulatory and healthcare-market expectations.

  Source

• 2020Hualan Biological participates in COVID-19 vaccine development efforts

  Hualan Biological and related vaccine operations pursued COVID-19 vaccine research during the pandemic, adding pandemic-response development to the company's existing vaccine activities.

  Product launchOther
  Source
• 2004Hualan Biological lists on the Shenzhen Stock Exchange

  The company became a publicly traded enterprise on the Shenzhen Stock Exchange, providing access to public capital for expansion of its biological-products business.

  Other
  Source

1. Hualan Biological official website
2. Shenzhen Stock Exchange